GSA Capital Partners LLP Invests $1.02 Million in Insulet Co. (NASDAQ:PODD)

GSA Capital Partners LLP bought a new stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,370 shares of the medical instruments supplier's stock, valued at approximately $1,017,000.

Several other large investors have also recently made changes to their positions in PODD. Wedmont Private Capital increased its holdings in Insulet by 3.5% during the third quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier's stock worth $326,000 after buying an additional 48 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 58 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in Insulet by 1.1% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier's stock valued at $1,264,000 after purchasing an additional 66 shares during the last quarter. Greenleaf Trust grew its holdings in Insulet by 4.2% during the third quarter. Greenleaf Trust now owns 1,783 shares of the medical instruments supplier's stock valued at $415,000 after purchasing an additional 72 shares during the period. Finally, UMB Bank n.a. increased its position in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock worth $37,000 after buying an additional 81 shares during the last quarter.

Insulet Price Performance

Insulet stock traded down $1.04 during midday trading on Friday, hitting $260.12. 916,752 shares of the company's stock were exchanged, compared to its average volume of 780,524. The company has a market cap of $18.25 billion, a P/E ratio of 44.54, a PEG ratio of 4.11 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a 50-day moving average price of $237.77 and a two-hundred day moving average price of $207.47. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of recent research reports. Citigroup upped their price target on Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research report on Tuesday, October 1st. Morgan Stanley upped their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a report on Monday, November 11th. Sanford C. Bernstein started coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 target price for the company. Piper Sandler upped their price target on shares of Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Finally, Barclays raised their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an "equal weight" rating in a report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average price target of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.